An emerging treatment option for glaucoma: Rho kinase inhibitors

Sean K Wang,1 Robert T Chang21Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USAAbstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang SK, Chang RT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6ad1cf805a8448588824577ee1627ab6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ad1cf805a8448588824577ee1627ab6
record_format	dspace
spelling	oai:doaj.org-article:6ad1cf805a8448588824577ee1627ab62021-12-02T05:54:21ZAn emerging treatment option for glaucoma: Rho kinase inhibitors1177-5483https://doaj.org/article/6ad1cf805a8448588824577ee1627ab62014-05-01T00:00:00Zhttp://www.dovepress.com/an-emerging-treatment-option-for-glaucoma-rho-kinase-inhibitors-a16776https://doaj.org/toc/1177-5483 Sean K Wang,1 Robert T Chang21Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USAAbstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This results in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. There are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. Given the multiple beneficial effects for glaucoma patients, ROCK inhibitors are certainly a highly anticipated emerging treatment option for glaucoma.Keywords: ROCK inhibitors, actin cytoskeleton, aqueous dynamics reviewWang SKChang RTDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 883-890 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Wang SK Chang RT An emerging treatment option for glaucoma: Rho kinase inhibitors
description	Sean K Wang,1 Robert T Chang21Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USAAbstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This results in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. There are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. Given the multiple beneficial effects for glaucoma patients, ROCK inhibitors are certainly a highly anticipated emerging treatment option for glaucoma.Keywords: ROCK inhibitors, actin cytoskeleton, aqueous dynamics review
format	article
author	Wang SK Chang RT
author_facet	Wang SK Chang RT
author_sort	Wang SK
title	An emerging treatment option for glaucoma: Rho kinase inhibitors
title_short	An emerging treatment option for glaucoma: Rho kinase inhibitors
title_full	An emerging treatment option for glaucoma: Rho kinase inhibitors
title_fullStr	An emerging treatment option for glaucoma: Rho kinase inhibitors
title_full_unstemmed	An emerging treatment option for glaucoma: Rho kinase inhibitors
title_sort	emerging treatment option for glaucoma: rho kinase inhibitors
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/6ad1cf805a8448588824577ee1627ab6
work_keys_str_mv	AT wangsk anemergingtreatmentoptionforglaucomarhokinaseinhibitors AT changrt anemergingtreatmentoptionforglaucomarhokinaseinhibitors AT wangsk emergingtreatmentoptionforglaucomarhokinaseinhibitors AT changrt emergingtreatmentoptionforglaucomarhokinaseinhibitors
_version_	1718400176606937088

An emerging treatment option for glaucoma: Rho kinase inhibitors

Ejemplares similares